drugset
drugset / Trial / NCT06041841

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

NCT06041841 ↗

Phase 2 Unknown 4 enrolled LG Chem
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity

Timeline

Start
2023-12
Primary completion
2024-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LB54640 Unknown — Oral

Indications

obesity due to leptin receptor gene deficiency obesity due to pro-opiomelanocortin deficiency obesity due to prohormone convertase I deficiency